- Coordinator
- Hydrumedical SA, Portugal
- Runs
- 1 December 2023 to 30 November 2025
- Status
- Running
- EU funding
- €1.5m
- Total cost
- €2.2m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190169028
What the project is doing
In the project's own words, from its summary on CORDIS.
Hydrumedical S.A. (HYD) team is composed by a urologist and biomaterials scientists that will revolutionise the treatment of ureteral disorders. Hydrustent is a biodegradable, hydrogel-based, soft, lubricated, and flexible stent. These properties prevent bacterial adhesion (>80% of the stent-related complications) and encrustation development. Nowadays, the application of stents requires a 2nd removal procedure, a burden for patients and healthcare systems.
Hydrustent is homogeneously degraded by the urine flow within 7-10 days, eliminating the need of further interventions for its removal. Hydrustent will bring huge health benefits for patients and reduce up to 60% of treatment costs (4.3B€ savings for the health system in EU+US). Validated by the urology community, with a global Ureteral Stents Market raising (~604M€ by 2030), if Hydrustent project is successfully implemented, we intend to reach the EU market in 2024 with profits amounting to 25M€, 5 years after product launch.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Hydrumedical SA | Guimaraes | Portugal | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI